The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: Correlation to histomorphometric indices of turnover

Babul Borah, Erik L. Ritman, Thomas E. Dufresne, Steven M. Jorgensen, Sheng Liu, Jarek Sacha, Roger J. Phipps, Russell T. Turner

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

The primary goal of our study was to determine changes in bone mineralization in postmenopausal osteoporotic women treated for 3 years with risedronate or placebo. A secondary goal was to determine the relationship between mineralization and indices of bone turnover measured on the same biopsies. The degree of mineralization was measured by micro-computed tomography using Synchrotron radiation (Synchrotron μCT) in the trabecular bone of paired transiliac biopsies taken at baseline and after 3 years of treatment from patients receiving risedronate 5 mg daily (n = 11) or placebo (n = 8). In the risedronate-treated patients, the average mineralization (Avg-MIN) and peak mineralization (Peak-MIN) at 3 years were significantly increased from baseline by 4.7% (P < 0.0001) and 5.4% (P = 0.0003), respectively and showed significant negative correlation to turnover indices. In the placebo-treated patients, the increases in Avg-MIN (2.0%) and Peak-MIN (1.6%) were not significantly different from baseline and correlation to turnover indices was weaker. Risedronate significantly reduced the ratio of low- to high-mineralized bone fractions estimated by volume (BMR-V) and surface area (BMR-S) by 70.1% and 54.1%, respectively from baseline. These changes were consistent with the significant reduction of turnover from baseline assessed by reductions in mineralizing surface, MS/BS (-72.8%); activation frequency, Ac.F (-60.4%); and bone formation rate, BFR-BV (-63.6%) in the same biopsies in the risedronate-treated patients. Comparing the pair-wise changes from baseline, risedronate significantly reduced the low-mineralized bone fraction in comparison to placebo, as indicated by a larger reduction of BMR-V (P = 0.015) and BMR-S (P = 0.035). In the risedronate group, BMR-V and BMR-S showed significant positive correlation to MS/BS (R 2: 0.83 and 0.92, respectively). The correlations to Ac.F and BFR-BV were also significant, with BMR-S showing a strong relation (R 2: 0.77 and 0.79, respectively). The data suggest that BMR-V and BMR-S are markers of turnover of trabecular bone and may be used to assess treatment effect on turnover in bone biopsies. The results demonstrate that the reduction of turnover by risedronate increased the degree of mineralization and reduced the ratio of low- to high-mineralized bone fractions which may increase bone's resistance to fracture.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalBone
Volume37
Issue number1
DOIs
StatePublished - Jul 2005

Fingerprint

Physiologic Calcification
Synchrotrons
Tomography
Radiation
Placebos
Biopsy
Bone and Bones
Bone Remodeling
Risedronate Sodium
Osteogenesis
Therapeutics

Keywords

  • Bone turnover
  • Mineralization
  • Osteoporosis
  • Risedronate
  • Synchrotron

ASJC Scopus subject areas

  • Physiology
  • Hematology

Cite this

The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation : Correlation to histomorphometric indices of turnover. / Borah, Babul; Ritman, Erik L.; Dufresne, Thomas E.; Jorgensen, Steven M.; Liu, Sheng; Sacha, Jarek; Phipps, Roger J.; Turner, Russell T.

In: Bone, Vol. 37, No. 1, 07.2005, p. 1-9.

Research output: Contribution to journalArticle

Borah, Babul ; Ritman, Erik L. ; Dufresne, Thomas E. ; Jorgensen, Steven M. ; Liu, Sheng ; Sacha, Jarek ; Phipps, Roger J. ; Turner, Russell T. / The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation : Correlation to histomorphometric indices of turnover. In: Bone. 2005 ; Vol. 37, No. 1. pp. 1-9.
@article{c053e312ef7b45a7ae5a5bf1721b7199,
title = "The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: Correlation to histomorphometric indices of turnover",
abstract = "The primary goal of our study was to determine changes in bone mineralization in postmenopausal osteoporotic women treated for 3 years with risedronate or placebo. A secondary goal was to determine the relationship between mineralization and indices of bone turnover measured on the same biopsies. The degree of mineralization was measured by micro-computed tomography using Synchrotron radiation (Synchrotron μCT) in the trabecular bone of paired transiliac biopsies taken at baseline and after 3 years of treatment from patients receiving risedronate 5 mg daily (n = 11) or placebo (n = 8). In the risedronate-treated patients, the average mineralization (Avg-MIN) and peak mineralization (Peak-MIN) at 3 years were significantly increased from baseline by 4.7{\%} (P < 0.0001) and 5.4{\%} (P = 0.0003), respectively and showed significant negative correlation to turnover indices. In the placebo-treated patients, the increases in Avg-MIN (2.0{\%}) and Peak-MIN (1.6{\%}) were not significantly different from baseline and correlation to turnover indices was weaker. Risedronate significantly reduced the ratio of low- to high-mineralized bone fractions estimated by volume (BMR-V) and surface area (BMR-S) by 70.1{\%} and 54.1{\%}, respectively from baseline. These changes were consistent with the significant reduction of turnover from baseline assessed by reductions in mineralizing surface, MS/BS (-72.8{\%}); activation frequency, Ac.F (-60.4{\%}); and bone formation rate, BFR-BV (-63.6{\%}) in the same biopsies in the risedronate-treated patients. Comparing the pair-wise changes from baseline, risedronate significantly reduced the low-mineralized bone fraction in comparison to placebo, as indicated by a larger reduction of BMR-V (P = 0.015) and BMR-S (P = 0.035). In the risedronate group, BMR-V and BMR-S showed significant positive correlation to MS/BS (R 2: 0.83 and 0.92, respectively). The correlations to Ac.F and BFR-BV were also significant, with BMR-S showing a strong relation (R 2: 0.77 and 0.79, respectively). The data suggest that BMR-V and BMR-S are markers of turnover of trabecular bone and may be used to assess treatment effect on turnover in bone biopsies. The results demonstrate that the reduction of turnover by risedronate increased the degree of mineralization and reduced the ratio of low- to high-mineralized bone fractions which may increase bone's resistance to fracture.",
keywords = "Bone turnover, Mineralization, Osteoporosis, Risedronate, Synchrotron",
author = "Babul Borah and Ritman, {Erik L.} and Dufresne, {Thomas E.} and Jorgensen, {Steven M.} and Sheng Liu and Jarek Sacha and Phipps, {Roger J.} and Turner, {Russell T.}",
year = "2005",
month = "7",
doi = "10.1016/j.bone.2005.03.017",
language = "English (US)",
volume = "37",
pages = "1--9",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation

T2 - Correlation to histomorphometric indices of turnover

AU - Borah, Babul

AU - Ritman, Erik L.

AU - Dufresne, Thomas E.

AU - Jorgensen, Steven M.

AU - Liu, Sheng

AU - Sacha, Jarek

AU - Phipps, Roger J.

AU - Turner, Russell T.

PY - 2005/7

Y1 - 2005/7

N2 - The primary goal of our study was to determine changes in bone mineralization in postmenopausal osteoporotic women treated for 3 years with risedronate or placebo. A secondary goal was to determine the relationship between mineralization and indices of bone turnover measured on the same biopsies. The degree of mineralization was measured by micro-computed tomography using Synchrotron radiation (Synchrotron μCT) in the trabecular bone of paired transiliac biopsies taken at baseline and after 3 years of treatment from patients receiving risedronate 5 mg daily (n = 11) or placebo (n = 8). In the risedronate-treated patients, the average mineralization (Avg-MIN) and peak mineralization (Peak-MIN) at 3 years were significantly increased from baseline by 4.7% (P < 0.0001) and 5.4% (P = 0.0003), respectively and showed significant negative correlation to turnover indices. In the placebo-treated patients, the increases in Avg-MIN (2.0%) and Peak-MIN (1.6%) were not significantly different from baseline and correlation to turnover indices was weaker. Risedronate significantly reduced the ratio of low- to high-mineralized bone fractions estimated by volume (BMR-V) and surface area (BMR-S) by 70.1% and 54.1%, respectively from baseline. These changes were consistent with the significant reduction of turnover from baseline assessed by reductions in mineralizing surface, MS/BS (-72.8%); activation frequency, Ac.F (-60.4%); and bone formation rate, BFR-BV (-63.6%) in the same biopsies in the risedronate-treated patients. Comparing the pair-wise changes from baseline, risedronate significantly reduced the low-mineralized bone fraction in comparison to placebo, as indicated by a larger reduction of BMR-V (P = 0.015) and BMR-S (P = 0.035). In the risedronate group, BMR-V and BMR-S showed significant positive correlation to MS/BS (R 2: 0.83 and 0.92, respectively). The correlations to Ac.F and BFR-BV were also significant, with BMR-S showing a strong relation (R 2: 0.77 and 0.79, respectively). The data suggest that BMR-V and BMR-S are markers of turnover of trabecular bone and may be used to assess treatment effect on turnover in bone biopsies. The results demonstrate that the reduction of turnover by risedronate increased the degree of mineralization and reduced the ratio of low- to high-mineralized bone fractions which may increase bone's resistance to fracture.

AB - The primary goal of our study was to determine changes in bone mineralization in postmenopausal osteoporotic women treated for 3 years with risedronate or placebo. A secondary goal was to determine the relationship between mineralization and indices of bone turnover measured on the same biopsies. The degree of mineralization was measured by micro-computed tomography using Synchrotron radiation (Synchrotron μCT) in the trabecular bone of paired transiliac biopsies taken at baseline and after 3 years of treatment from patients receiving risedronate 5 mg daily (n = 11) or placebo (n = 8). In the risedronate-treated patients, the average mineralization (Avg-MIN) and peak mineralization (Peak-MIN) at 3 years were significantly increased from baseline by 4.7% (P < 0.0001) and 5.4% (P = 0.0003), respectively and showed significant negative correlation to turnover indices. In the placebo-treated patients, the increases in Avg-MIN (2.0%) and Peak-MIN (1.6%) were not significantly different from baseline and correlation to turnover indices was weaker. Risedronate significantly reduced the ratio of low- to high-mineralized bone fractions estimated by volume (BMR-V) and surface area (BMR-S) by 70.1% and 54.1%, respectively from baseline. These changes were consistent with the significant reduction of turnover from baseline assessed by reductions in mineralizing surface, MS/BS (-72.8%); activation frequency, Ac.F (-60.4%); and bone formation rate, BFR-BV (-63.6%) in the same biopsies in the risedronate-treated patients. Comparing the pair-wise changes from baseline, risedronate significantly reduced the low-mineralized bone fraction in comparison to placebo, as indicated by a larger reduction of BMR-V (P = 0.015) and BMR-S (P = 0.035). In the risedronate group, BMR-V and BMR-S showed significant positive correlation to MS/BS (R 2: 0.83 and 0.92, respectively). The correlations to Ac.F and BFR-BV were also significant, with BMR-S showing a strong relation (R 2: 0.77 and 0.79, respectively). The data suggest that BMR-V and BMR-S are markers of turnover of trabecular bone and may be used to assess treatment effect on turnover in bone biopsies. The results demonstrate that the reduction of turnover by risedronate increased the degree of mineralization and reduced the ratio of low- to high-mineralized bone fractions which may increase bone's resistance to fracture.

KW - Bone turnover

KW - Mineralization

KW - Osteoporosis

KW - Risedronate

KW - Synchrotron

UR - http://www.scopus.com/inward/record.url?scp=20544449394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20544449394&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2005.03.017

DO - 10.1016/j.bone.2005.03.017

M3 - Article

C2 - 15894527

AN - SCOPUS:20544449394

VL - 37

SP - 1

EP - 9

JO - Bone

JF - Bone

SN - 8756-3282

IS - 1

ER -